Civitas Therapeutics has received a $1 million grant from The Michael J. Fox Foundation for Parkinson’s Research for development of CVT-301 inhaled L-dopa for the treatment of motor fluctuations in Parkinson’s disease patients, the company said. The grant will support a Phase 2b trial of the carrier-free dry powder formulation. The foundation previously awarded Civitas a grant in November 2011 for Phase 1 clinical development.
In April 2013, the company announced positive topline results from a Phase 2a study of CVT-301. The formulation is based on Civitas’s Arcus powder technology and delivered by the Arcus breath-actuated inhaler.
Civitas Founder and Chief Scientific Officer Rick Batycky commented, “The enthusiasm and support of MJFF for CVT-301 has been extraordinarily valuable in our efforts. In addition to its financial contributions, the Foundation’s ability to help connect us with patients, thought leaders and other important stakeholders has contributed to our rapid progress. We receive consistent feedback that our simple product configuration is uniquely suited for this patient population and this furthers our confidence that CVT-301 has the potential to provide a transformative benefit to those suffering from this devastating disease.”
Read the Civitas press release.
